Local Thrombolytics Before Thrombectomy in STEMI

NCT ID: NCT01568931

Last Updated: 2020-04-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background Prompt reperfusion with percutaneous coronary intervention (PCI) in the setting of ST-elevation myocardial infarction (STEMI) improves clinical outcomes through salvage of myocardial tissue.

Although the use of thrombus aspiration with PCI can result in improved rates of normal epicardial flow and myocardial perfusion, several unmet needs remain.

Purpose The purpose of this trial will be to evaluate the hypothesis that local delivery of thrombolytics vs. saline infusion prior to thrombus aspiration and PCI is safe and effective in patients with STEMI.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will select patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing manual thrombectomy followed by primary percutaneous coronary intervention (PCI).

Patients will be randomized to receive local bolus of 200,000 units urokinase or saline solution

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Urokinase

Patients will be randomized to to receive local bolus of 200,000 units urokinase

Group Type ACTIVE_COMPARATOR

Urokinase

Intervention Type DRUG

intracoronary, urokinase, 200,000 Units, bolus

Saline

Patients will be randomized to to receive local bolus of intracoronary saline

Group Type ACTIVE_COMPARATOR

Saline

Intervention Type DRUG

intracoronary, saline, bolus 1 cc

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Urokinase

intracoronary, urokinase, 200,000 Units, bolus

Intervention Type DRUG

Saline

intracoronary, saline, bolus 1 cc

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UROKINASE-R, IMARX THERAPEUTICS INC., Tucson, AZ Saline infusion

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ST-elevation myocardial infarction
* angiographic evidence of massive thrombosis in the culprit artery
* Indication to manual thrombectomy followed by primary percutaneous coronary intervention (PCI)
* Able to understand and willing to sign the informed CF

Exclusion Criteria

* Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before CT
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Roma La Sapienza

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francesco Pelliccia

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cesare Greco, MD

Role: STUDY_DIRECTOR

University Sapienza

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

197/2012/D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nitric Oxide in Myocardial Infarction Size
NCT00568061 TERMINATED PHASE2